5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy

By J. Christman. Oncogene, 2002

1,471 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

DNA methylation and cancer. (2010, background): “By now, themost studied and promising demethylation agents, commonly used in everyday laboratory practice, are 5-azacytidine (5-Aza-CR, vidaza) and 5-aza-20-deoxycytidine (5-Aza-CdR, decitabine) (Christman, 2002).”
Metabolic reprogramming and epigenetic modifications on the path to cancer (2021, background): “Azacitidine and decitabine were first synthesized almost 60 years ago (Evans and Mengel, 1964; Sorm et al., 1964; Christman, 2002).”